Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping.
Brief Summary: The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at 5 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm -related morbidity and all-cause mortality within 6 weeks post-aSAH treated by surgical clipping. The primary endpoint of the study is the occurrence of cerebral vasospasm-related morbidity, and mortality of all-causes within 6 weeks post-aSAH, defined by at least one of the following:

1. Death (all causes).
2. New cerebral infarct(s) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm.
3. Delayed ischemic neurological deficit (DIND) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm.
4. Neurological signs or symptoms (depending on state of consciousness), in the presence of confirmed cerebral vasospasm on angiography (DSA or CTA), leading to the administration of a valid rescue therapy.

An independent Critical Events Committee (CEC) will adjudicate whether or not patients meet the primary endpoint and its individual morbidity components.


Options:
A: Arm Label: Clazosentan; Type: EXPERIMENTAL; Interventions: Drug: Clazosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Clazosentan; Assigned to Arm(s): Clazosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Standard SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Arm Label: Intensive SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Intervention Type: DRUG; Name: Intravenous nicardipine hydrochloride; Assigned to Arm(s): Intensive SBP Reduction Arm, Standard SBP Reduction Arm
C: Intervention Type: DRUG; Name: Labetalol Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metoprolol tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Hydralazine Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Glycerol Trinitrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Phentolamine mesylate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nicardipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Urapidil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Esmolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Enalaprilat; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nitroprusside; Assigned to Arm(s): N/A
D: Arm Label: Candesartan Cilexetil; Type: EXPERIMENTAL; Interventions: Drug: Candesartan Cilexetil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Candesartan Cilexetil; Assigned to Arm(s): Candesartan Cilexetil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A